# PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders

View Online

1.

Smith, K.S., Rudolph, U.: Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. Neuropharmacology. 62, 54–62 (2012). https://doi.org/10.1016/j.neuropharm.2011.07.026.

2.

Luscher, B., Shen, Q., Sahir, N.: The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry. 16, 383–406 (2011). https://doi.org/10.1038/mp.2010.120.

3.

Balon, R.: Mood, anxiety, and physical illness: body and mind, or mind and body? Depression and Anxiety. 23, 377–387 (2006). https://doi.org/10.1002/da.20217.

4.

Kalueff, A.V., Nutt, D.J.: Role of GABA in anxiety and depression. Depression and Anxiety. 24, 495–517 (2007). https://doi.org/10.1002/da.20262.

5.

Cryan, J.F., Kaupmann, K.: Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences. 26, 36–43 (2005). https://doi.org/10.1016/j.tips.2004.11.004.

6.

Holmes, A., Heilig, M., Rupniak, N.M.J., Steckler, T., Griebel, G.: Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences. 24, 580–588 (2003). https://doi.org/10.1016/j.tips.2003.09.011.

7.

Levine, J., Cole, D.P., Chengappa, K.N.R., M.D., S.G.: Anxiety disorders and major depression, together or apart. Depression and Anxiety. 14, 94–104 (2001). https://doi.org/10.1002/da.1051.

8.

Freund, T.F.: Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends in Neurosciences. 26, 489–495 (2003). https://doi.org/10.1016/S0166-2236(03)00227-3.

9.

Strange, P.G.: Brain biochemistry and brain disorders. Oxford University Press, Oxford (1992).

10.

Carvalho, A.F., Van Bockstaele, E.J.: Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 38, 59–67 (2012). https://doi.org/10.1016/j.pnpbp.2012.01.008.

11.

Atwood, B.K., Straiker, A., Mackie, K.: CB2: Therapeutic target-in-waiting. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 38, 16–20 (2012). https://doi.org/10.1016/j.pnpbp.2011.12.001.

12.

Hill, A.J., Williams, C.M., Whalley, B.J., Stephens, G.J.: Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics. 133, 79–97 (2012).

https://doi.org/10.1016/j.pharmthera.2011.09.002.

13.

Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy, https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf.

14.

H. Attarian, O.A.: Treatment of disorders of hypersomnolence. 16, 302–302.

15.

N.P. Robertson, K.J.P.: Narcolepsy: environment, genes and treatment. 261, 1644–1646 (2014).

16.

Cera, N., Tartaro, A., Sensi, S.L.: Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE. 9, (2014). https://doi.org/10.1371/journal.pone.0107145.

17.

Saper, C.B., Scammell, T.E.: Emerging therapeutics in sleep. Annals of Neurology. 74, 435–440 (2013). https://doi.org/10.1002/ana.24000.

18.

Eric J. Olson, K.R.: Management of common sleep disorders. 88, 231–238 (2013).

19.

Hoyer, D., Jacobson, L.H.: Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides. 47, 477–488 (2013). https://doi.org/10.1016/j.npep.2013.10.009.

20.

Carlos H. Schenck, M.W.M.: Insights from studying human sleep disorders. 437, 1279–1285 (2005).

21.

Stores, G.: Medication for sleep-wake disorders. Archives of Disease in Childhood. 88, 899–903 (2003). https://doi.org/10.1136/adc.88.10.899.

22.

Kilduff, T.S., Peyron, C.: The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences. 23, 359–365 (2000). https://doi.org/10.1016/S0166-2236(00)01594-0.

23.

Brisbare-Roch, C.: Promotion of sleep by targeting the orexin system in rats, dogs and humans. 13, 150–155 (2007).

24.

Mark W. Mahowald MD: Pathophysiologic mechanisms in REM sleep behavior disorder. Current Neurology and Neuroscience Reports. 7, 167–172 (2007). https://doi.org/10.1007/s11910-007-0013-7.

25.

Mahowald, M.W., Schenck, C.H.: Dissociated states of wakefulness and sleep. Neurology. 42 Suppl. 6, 44–52 (1992).